-
公开(公告)号：US20240166708A1
公开(公告)日：2024-05-23
申请号：US18347246
申请日：2023-07-05
IPC分类号： C07K14/575 , A61P3/04
CPC分类号： C07K14/575 , A61P3/04 , A61K38/00
摘要： This invention relates to isolated polypeptides that are long acting analogs of human PYY. The disclosed PYY analog polypeptides have beneficial physicochemical properties relative to endogenous PYY and known synthetic PYY analog polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed PYY analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed PYY analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
-
公开(公告)号：US11739134B2
公开(公告)日：2023-08-29
申请号：US17233111
申请日：2021-04-16
IPC分类号： C07K14/575 , A61P3/04 , A61K38/00
CPC分类号： C07K14/575 , A61P3/04 , A61K38/00
摘要： This invention relates to isolated polypeptides that are long acting analogs of human PYY. The disclosed PYY analog polypeptides have beneficial physicochemical properties relative to endogenous PYY and known synthetic PYY analog polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed PYY analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed PYY analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
-
公开(公告)号：USD840030S1
公开(公告)日：2019-02-05
申请号：US29566823
申请日：2016-06-02
设计人： Jay S. Smith , Michael R. Cole , Amy K. Whitson
-
公开(公告)号：USD835783S1
公开(公告)日：2018-12-11
申请号：US29604792
申请日：2017-05-19
设计人： Jay S. Smith , Michael R. Cole , Amy K. Whitson
-
公开(公告)号：US09682127B2
公开(公告)日：2017-06-20
申请号：US15291523
申请日：2016-10-12
IPC分类号： A61K38/26 , A61K9/00 , A61K9/10 , A61K9/16 , A61K9/70 , A61K47/14 , C07K7/06 , C07K14/605 , A61K47/12 , A61K47/20 , A61K47/26 , A61K47/32
CPC分类号： A61K38/26 , A61K9/0004 , A61K9/0024 , A61K9/10 , A61K9/1617 , A61K9/1623 , A61K9/7023 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/26 , A61K47/32 , C07K7/067 , C07K14/605 , Y10T29/494
摘要： A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.
-
6.发明申请Devices, Formulations, and Methods for Delivery of Multiple Beneficial Agents 有权用于交付多种有益药剂的装置，配方和方法公开(公告)号：US20130090287A1
公开(公告)日：2013-04-11
申请号：US13689410
申请日：2012-11-29
申请人： Thomas R. Alessi , Karling Alice Leung , Ryan D. Mercer , Cristina G. Negulescu , Catherine M. Rohloff , Bing Yang
发明人： Thomas R. Alessi , Karling Alice Leung , Ryan D. Mercer , Cristina G. Negulescu , Catherine M. Rohloff , Bing Yang
IPC分类号： A61K47/32
CPC分类号： A61K9/0004 , A61K9/0024 , A61K9/1617 , A61K9/1623 , A61K9/5084 , A61K38/22 , A61K38/2264 , A61K38/2278 , A61K38/26 , A61K45/06 , A61K47/14 , A61K47/32 , A61K2300/00
摘要： The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.
摘要翻译： 本发明涉及用于递送两种或多种有益试剂的渗透递送装置，制剂和方法。 一方面，本发明提供了用于基本上同时施用两种或更多种有益剂的渗透递送装置。 另一方面，本发明提供用于渗透递送装置的有益剂制剂。 制剂包括其中有益剂可溶于载体的制剂，包含一种或多种有益剂的颗粒制剂的悬浮制剂及其组合。 此外，公开了使用两种或更多种有益剂治疗各种疾病或病症的方法，其中优选使用本发明的渗透递送装置和/或制剂来实施所述方法。
-
7.发明授权公开(公告)号：US08372424B2
公开(公告)日：2013-02-12
申请号：US13596971
申请日：2012-08-28
摘要： This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10−7 reciprocal second.
-
8.发明申请公开(公告)号：US20120322720A1
公开(公告)日：2012-12-20
申请号：US13596971
申请日：2012-08-28
摘要： This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10−7 reciprocal second.
-
公开(公告)号：US08299025B2
公开(公告)日：2012-10-30
申请号：US12148896
申请日：2008-04-22
CPC分类号： A61K38/26 , A61K9/0004 , A61K9/0024 , A61K9/10 , A61K9/1617 , A61K9/1623 , A61K9/7023 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/26 , A61K47/32 , C07K7/067 , C07K14/605 , Y10T29/494
摘要： A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.
-
10.发明申请Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers 审中-公开组合物，装置及其使用方法用于治疗癌症公开(公告)号：US20120208755A1
公开(公告)日：2012-08-16
申请号：US13372326
申请日：2012-02-13
申请人： Karling Alice Leung
发明人： Karling Alice Leung
CPC分类号： A61K38/26 , A61K45/06 , A61M31/002 , A61M37/00 , C07K14/605
摘要： The use of GLP-1 receptor agonists, such as glucagon-like peptide-1 (GLP-1) or exenatide, for the treatment of cancer is described. The GLP-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the GLP-1 receptor agonist for at least one month. Additional beneficial agents, such as anticancer agents, can also be administered.
摘要翻译： 描述了GLP-1受体激动剂如胰高血糖素样肽-1（GLP-1）或艾塞那肽用于治疗癌症的用途。 GLP-1受体激动剂通常使用植入的渗透递送装置递送，其提供GLP-1受体激动剂连续递送至少一个月。 还可以施用另外的有益剂，例如抗癌剂。
-
-
-
-
-
-
-
-
-
搜索结果
108 条记录 (耗时 0.04 秒)
